2017
Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support
Wang T, O’Brien E, Rogers JG, Jacoby DL, Chen ME, Testani JM, Bowles DE, Milano CA, Felker GM, Patel CB, Bonde PN, Ahmad T. Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. ASAIO Journal 2017, 63: 536-541. PMID: 28319523, PMCID: PMC5585122, DOI: 10.1097/mat.0000000000000564.Peer-Reviewed Original ResearchConceptsLVAD supportHeart failureMechanically Assisted Circulatory Support level 1Continuous-flow LVAD implantationLong-term LVAD supportMiR-155Ventricular assist device therapyMicroRNA-155Ventricular assist device supportPost-LVAD placementAdverse clinical outcomesAssist device supportPlasma expression levelsSupport level 1Real-time polymerase chain reactionQuantitative real-time polymerase chain reactionRelative quantification valuesContinuous blood flowWilcoxon signed-rank testMultiple biologic processesLVAD physiologyMeasurement of miRNAsInteragency RegistryLVAD implantationHF pathogenesis
2014
The Incidence, Risk, and Consequences of Atrial Arrhythmias in Patients with Continuous‐Flow Left Ventricular Assist Devices
Brisco MA, Sundareswaran KS, Milano CA, Feldman D, Testani JM, Ewald GA, Slaughter MS, Farrar DJ, Goldberg LR, Investigators F. The Incidence, Risk, and Consequences of Atrial Arrhythmias in Patients with Continuous‐Flow Left Ventricular Assist Devices. Journal Of Cardiac Surgery 2014, 29: 572-580. PMID: 24750460, DOI: 10.1111/jocs.12336.Peer-Reviewed Original ResearchConceptsLeft ventricular assist deviceLate atrial arrhythmiaAtrial arrhythmiasVentricular assist deviceFunctional statusRisk factorsAssist deviceHeartMate II Left Ventricular Assist DeviceIncidence of AASix-minute walk distanceDestination therapy trialsDays of supportStrong risk factorQuality of lifePreoperative creatinineLVAD patientsSerum creatinineWalk distanceEjection fractionHeart failureLVAD supportQOL improvementMultivariable modelSimilar survivalBlanking period